Forecast

There is no analyst data available for this company.

News Go to news feed

Enzon Pharmaceuticals posts EPS of -$0.35 for quarter ended June 30, 2026

Enzon Pharmaceuticals reported earnings per share of -$0.35 for the quarter ended June 30, 2026, compared with -$2.00 in the year-ago quarter. The figures were presented at the financial conference for the quarter end on August 3, 2026. » More on finanzen.net
Enzon Pharmaceuticals reports quarterly loss per share of $0.84

Enzon Pharmaceuticals released figures for the quarter ended March 31, 2026, and reported a loss per share of $0.84. In the same quarter last year the loss was $1.00 per share. No further financial metrics were disclosed in the report. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2019, Enzon Pharmaceuticals has already paid €0.16 in dividends. The last payout was in October 2019.

Financials

In the last quarter, Enzon Pharmaceuticals had revenue of €78.97M and net profit of -€4.44M

(EUR)	June 2026	YoY
Revenue	78.97M	-
Gross profit	9.72M	-
Net profit	-4.44M	428.06%
EBITDA	2.36M	986.06%

Fundamentals

Metric	Value
Market capitalization	€26.74M
Number of shares	6.61M
52-week high/low	€29.02 - €3.43
Dividends	No
Beta	-0.04
P/E ratio	-0.91
PEG ratio	0.01
P/B ratio	0.36
P/S ratio	0.18

Company profile

Enzon Pharmaceuticals, Inc. ist zusammen mit seinen Tochtergesellschaften in der Vermarktung von Arzneimitteln tätig. Das vermarktete Arzneimittel des Unternehmens ist PegIntron. Es hat auch eine Marketing-Vereinbarung für das Medikament Vicineum. Das Unternehmen wurde 1981 gegründet und hat seinen Hauptsitz in Cranford, New Jersey.

Name	Enzon Pharmaceuticals
CEO	Thomas Dale Davis
Headquarters	Lombard, il USA
Website	enzon.com
Sector	Consumer Staples
Industry	Food Products
IPO	07/01/2019
Employees	1,582